U.S. flag

An official website of the United States government

NM_201384.3(PLEC):c.13168G>T (p.Val4390Leu) AND multiple conditions

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Jun 14, 2019
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001220065.8

Allele description [Variation Report for NM_201384.3(PLEC):c.13168G>T (p.Val4390Leu)]

NM_201384.3(PLEC):c.13168G>T (p.Val4390Leu)

Gene:
PLEC:plectin [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
8q24.3
Genomic location:
Preferred name:
NM_201384.3(PLEC):c.13168G>T (p.Val4390Leu)
HGVS:
  • NC_000008.11:g.143916653C>A
  • NG_012492.1:g.65093G>T
  • NM_000445.5:c.13249G>T
  • NM_201378.4:c.13126G>T
  • NM_201379.3:c.13102G>T
  • NM_201380.4:c.13579G>T
  • NM_201381.3:c.13072G>T
  • NM_201382.4:c.13168G>T
  • NM_201383.3:c.13180G>T
  • NM_201384.3:c.13168G>TMANE SELECT
  • NP_000436.2:p.Val4417Leu
  • NP_958780.1:p.Val4376Leu
  • NP_958781.1:p.Val4368Leu
  • NP_958782.1:p.Val4527Leu
  • NP_958783.1:p.Val4358Leu
  • NP_958784.1:p.Val4390Leu
  • NP_958785.1:p.Val4394Leu
  • NP_958786.1:p.Val4390Leu
  • NC_000008.10:g.144990821C>A
  • NM_000445.4:c.13249G>T
Protein change:
V4358L
Links:
dbSNP: rs1554669843
NCBI 1000 Genomes Browser:
rs1554669843
Molecular consequence:
  • NM_000445.5:c.13249G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_201378.4:c.13126G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_201379.3:c.13102G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_201380.4:c.13579G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_201381.3:c.13072G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_201382.4:c.13168G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_201383.3:c.13180G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_201384.3:c.13168G>T - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Epidermolysis bullosa simplex 5B, with muscular dystrophy (EBS5B)
Synonyms:
EPIDERMOLYSIS BULLOSA SIMPLEX AND LIMB-GIRDLE MUSCULAR DYSTROPHY; Epidermolysa bullosa simplex and limb girdle muscular dystrophy; Epidermolysis bullosa simplex with muscular dystrophy
Identifiers:
MONDO: MONDO:0009181; MedGen: C2931072; Orphanet: 257; OMIM: 226670
Name:
Epidermolysis bullosa simplex, Ogna type (EBS5A)
Synonyms:
EPIDERMOLYSIS BULLOSA SIMPLEX 5A, OGNA TYPE; Pidermolysis bullosa simplex 5A, Ogna type
Identifiers:
MONDO: MONDO:0007555; MedGen: C0432317; Orphanet: 79401; OMIM: 131950
Name:
Epidermolysis bullosa simplex 5C, with pyloric atresia (EBS5C)
Synonyms:
Epidermolysis bullosa simplex with pyloric atresia; PLEC1-Related Epidermolysis Bullosa with Pyloric Atresia
Identifiers:
MONDO: MONDO:0012807; MedGen: C2677349; Orphanet: 158684; OMIM: 612138
Name:
Autosomal recessive limb-girdle muscular dystrophy type 2Q (LGMDR17)
Synonyms:
Limb-girdle muscular dystrophy, type 2Q; MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 17
Identifiers:
MONDO: MONDO:0013390; MedGen: C3150989; Orphanet: 254361; OMIM: 613723
Name:
Epidermolysis bullosa simplex with nail dystrophy (EBS5D)
Identifiers:
MONDO: MONDO:0014661; MedGen: C4225309; OMIM: 616487

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV001392038Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))		Uncertain significance
(Jun 14, 2019) 		germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV001392038.5

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

This sequence change replaces valine with leucine at codon 4417 of the PLEC protein (p.Val4417Leu). The valine residue is highly conserved and there is a small physicochemical difference between valine and leucine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with PLEC-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024